Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of Zongertinib in Patients With HER2-mutated NSCLC in Japan (J-HERZ)

NCT07926308 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07926308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of Zongertinib in Patients With HER2-mutated NSCLC in Japan (J-HERZ)
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Not yet recruiting
Start date
November 17, 2026
Completion date
December 31, 2031
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer

Arms

As registered; 3 arms.

  • Zongertinib first-line treatment (1L) group Zongertinib

    Japanese patients with human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) have received their first systemic anticancer therapy for metastatic or locally advanced NSCLC.

  • Zongertinib second-line treatment (2L) group Zongertinib

    Japanese patients with HER2-mutated NSCLC have received their systemic anticancer therapy administered after one prior line of systemic therapy for metastatic or locally advanced NSCLC.

  • Zongertinib third-line treatment (3L) group Zongertinib

    Japanese patients with HER2-mutated NSCLC have received their systemic anticancer therapy administered after two prior lines of systemic therapy for metastatic or locally advanced NSCLC.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Real-world overall response rate (rwORR) in the zongertinib 1L group up to 4.6 years

Lead sponsor's other trials

Boehringer Ingelheim, most recent start first.

Similar trials

Same condition (Carcinoma, Non-Small-Cell Lung) and phase, most recent start first.